An implantable hemodialyzer for treatment of End-Stage Renal Disease

描述(由申请人提供)：终末期肾病(ESRD)在美国影响着60多万人，每年花费联邦医疗保险约330亿美元。中心内每周三次的血液透析是终末期肾病最常见的治疗方法，但它的5年存活率很低，降低了患者的生活质量，而且费用昂贵。相比之下，每日延长的血液透析显示出与肾移植相似的5年存活率，并改善了中期结果。尽管每日延长的血液透析比中心内每周三次的血液透析效果更好，但只有不到1%的ESRD人群进行这种透析，因为在中心内进行血液透析太昂贵，而且太复杂，不能在家里进行。目前的家庭血液透析系统要求患者和护理人员执行与危及生命的风险相关的复杂任务，如自我护理针棒。每日延长的家庭血液透析的卓越结果但采用率较低，为简单易用和安全的家庭血液透析系统创造了机会。我们项目的长期目标是创建一种新的家庭血液透析系统(NHHD)，该系统将增加每日延长的家庭血液透析的实践，并改善终末期肾病(ESRD)的预后。这份NIH SBIR第一阶段提案旨在证明nHHD的可行性，它将使终末期肾病患者能够进行每日延长的家庭血液透析，从而获得相关的健康益处。

DESCRIPTION (provided by applicant): End-Stage Renal Disease (ESRD) affects just over 600,000 people in the United States and costs Medicare ~$33 billion annually. In-center thrice-weekly hemodialysis is the most commonly performed treatment for ESRD, but it suffers from poor 5-year survival rates, reduced patient quality of life, and is costly. In contrast, daily-extended hemodialysis has demonstrated 5-year survival rates similar to kidney transplant and has improved intermediate outcomes. Even though daily-extended hemodialysis yields superior outcomes than in- center thrice-weekly hemodialysis, it is performed by less than 1% of the ESRD population because it is too costly to perform in-center and too complex to perform at home. Current home hemodialysis systems require patients and caregivers to perform complicated tasks associated with life threatening risks, such as self-care needle sticks. The superior outcomes but low adoption rate of daily-extended home hemodialysis creates an opportunity for a simple-to-use and safe home hemodialysis system. The long-term objective of our project is to create a new home hemodialysis system (nHHD) that will increase the practice of daily-extended home hemodialysis and improve End-Stage Renal Disease (ESRD) outcomes. This NIH SBIR Phase I proposal aims to demonstrate the feasibility of the nHHD that will empower ESRD patients to perform daily-extended home hemodialysis and consequently receive the associate health benefits.